Nxera Pharma Reports Revenue Growth Amidst Losses

Sosei Group Corporation ( (SOLTF) ) has released its Q1 earnings. Here is a breakdown of the information Sosei Group Corporation presented to its investors.

Nxera Pharma Co., Ltd is a biopharmaceutical company based in Japan, focusing on drug discovery and development, particularly targeting G Protein-Coupled Receptors (GPCRs) through its NxWave™ platform technology. The company operates in the pharmaceutical sector, with a strong presence in Japan, South Korea, and other Asia-Pacific markets.

In its latest earnings report for the first quarter of 2025, Nxera Pharma reported a significant increase in revenue, reaching JPY 6,644 million, a 44.1% rise compared to the same period last year. Despite this growth, the company still faced a net loss of JPY 760 million, although this was a marked improvement from the JPY 3,281 million loss in the previous year.

Key financial highlights include a core operating loss of JPY 625 million, down from JPY 931 million, and an operating loss of JPY 2,193 million, reduced from JPY 3,076 million. The company also made strategic advancements, such as entering agreements for the development and commercialization of new drug candidates in the Asia-Pacific region and progressing its extensive portfolio of novel drug programs.

Looking ahead, Nxera Pharma aims to continue leveraging its NxWave™ platform to deliver innovative medicines in Japan and APAC, while also expanding its pipeline through new partnerships and in-house developments. The company remains focused on achieving strategic growth and enhancing its drug discovery efforts.

Overall, Nxera Pharma’s management remains optimistic about the company’s future prospects, emphasizing continued investment in research and development and strategic partnerships to drive long-term growth.